influenza
-
GSK and Vir Terminate Influenza Alliance a Year After Ending Covid-19 R&D Pact
GSK and Vir Biotechnology have ended their influenza collaboration, a move that follows last year’s Phase 2 failure for one of the partnered programs. Vir is now free to continue its flu research on its own, but the company says it’s actively pursuing other partners.
-
The Public Health Emergency Is Expiring, So What Is the Future of Covid-19 Vaccines?
The FDA will decide this summer which strains the next Covid-19 vaccines should address. But companies are also taking a longer view, developing shots for the future that offer different features than the current ones and potentially broader protection against a wider range of pathogens.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Moderna Flu Vax Prompts Response to More Common Strains, But Misses in Influenza B
Moderna’s mRNA vaccine for influenza has early data from a pivotal study showing it met trial goals assessing immune response against the more common strains of the virus, but missed against two less common types. A separate and ongoing Phase 3 study is assessing efficacy.
-
Devices & Diagnostics, Sponsored Post
How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19
A webinar sponsored by BD scheduled for March 7 will explore how diagnostics companies are working with healthcare organizations to guard against the perfect storm of Covid-19, RSV and influenza. Register today!
-
GSK’s Covid-19 Valentine to Vir Biotech: ‘You Can Go Your Own Way’
GSK gave Vir Biotechnology a Valentine’s Day break-up message, but it’s not a complete goodbye. Though the two companies are ending their Covid-19 collaboration, they’ll still work together on other respiratory programs, including a prophylactic influenza antibody drug that is in mid-stage clinical development.
-
Devices & Diagnostics, Diagnostics
GRIP Molecular goes with graphene to put powerful diagnostics into patient hands
Diagnostics startup GRIP Molecular is developing an at-home test for Covid-19 and other respiratory infections. The technology builds on advances from several fields, including the discovery of graphene, a material that offers biocompatibility and conductivity.
-
GSK commits $345M to Vir as alliance expands to flu, other respiratory viruses
The amended pact follows a collaboration begun last year when GlaxoSmithKline paid Vir Biotechnology $250 million to team up on potential treatments for Covid-19. The expansion includes an influenza treatment based on Vir’s antibody technology.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
Artificial Intelligence, Diagnostics, Health Tech
Scripps researchers tap wearable data to track Covid-19 and flu
Scripps Research launched a new study to see if data collective from wearable devices could be used to track flu-like illnesses, including Covid-19. In January, Scripps published a retrospective study using a similar methodology showing that sleep and resting heart rate data from Fitbits were correlated with the number of patients reporting influenza-like illness.
-
Scripps study: Can your Fitbit track the flu?
A new study by the Scripps Research Translational Institute suggests Fitbits could be used to detect the flu. By tracking resting heart rate and activity levels, researchers said Fitbits could improve detection of outbreaks at the state level.
-
EMR data helps Boston Children’s predict flu cases in real time
The system’s estimates of national and regional flu activity had error rates 2- to 3-fold lower than earlier predictive models. It also correctly estimated the timing and magnitude of the national flu peak week.